Cigna takes different approach with GLP-1s, more favorable for Eli Lilly

Published 22/05/2025, 18:52
© Reuters

Investing.com -- Cigna’s Evernorth has introduced a new pharmacy benefit that caps out-of-pocket costs for GLP-1 weight loss medications at $200 per month, in a move analysts say is more favorable for Eli Lilly (NYSE:LLY) than rival models.

Announced late Wednesday, the offering covers Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. It is expected to provide lower costs for patients and employers, as well as other health plan businesses. 

Through direct negotiations with the drugmakers, Evernorth says patients can save up to $3,600 annually versus buying medications through consumer-facing channels.

“This is what Express Scripts does better than anyone: save Americans money on their prescriptions while helping them achieve their health goals,” said Evernorth Care Management President Adam Kautzner.

Morgan Stanley (NYSE:MS) analysts said the benefit structure “deviates significantly” from CVS’s recently announced formulary arrangement with Novo. 

“It’s an open access agreement which is aligned with [Eli Lilly’s] contracting strategy,” the firm noted after speaking with Lilly investor relations. 

They state that Zepbound and Wegovy will be broadly accessible across Cigna’s managed lives through at least 2026.

Mizuho (NYSE:MFG) said the new deals between drugmakers and payers “help to reiterate” that newer entrants like Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE) and Roche will struggle to generate returns. 

“Pricing [is] already getting squeezed… this is, though, excellent for patients,” analysts wrote.

Despite the discounting, Morgan Stanley believes Eli Lilly expects the pricing impact to remain within prior guidance. “There are no changes to the company’s 2025 portfolio pricing guidance of mid-to-high single digit price decline,” the bank wrote. 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.